Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Aurobindo Pharma launched Adquey, its first novel drug, in the US market. The drug was originally discovered by Otsuka Pharmaceutical and licensed to Aurobindo's arm Acrotech for US commercialisation.
Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey in the U.S. for the treatment of mild-to-moderate atopic dermatitis and established a dedicated dermatology business unit. The launch marks Acrotech's entry into the US dermatology market and expands the company's commercial presence.
Aurobindo Pharma's biopharmaceutical arm, Acrotech Biopharma Inc., has launched ADQUEY (difamilast 1%) ointment in the United States. The ointment is indicated for the treatment of mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and older.